VivoSeq
Metabolic & Endocrine

Diabetic Polyneuropathy

22

Pipeline Programs↗

2

Active Trials↗

16

Companies Involved↗

Diabetic Polyneuropathy is an emerging landscape with 22 programs across 16 companies. The most active players are Biogen, Tris Pharma, Inc., AstraZeneca. 5 therapies are approved with 4 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

48/100

Pipeline Velocity

11/100

Mech. Concentration

17/100

Completion Rate

85/100

Attrition Rate

12/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Biogen logo

Biogen

2 programs

Phase 1T

Tris Pharma, Inc.

2 programs

Phase 2AstraZeneca logo

AstraZeneca

2 programs

Phase 2Astellas logo

Astellas

1 program

Phase 2Tanabe Pharma Corporation logo

Tanabe Pharma Corporation

1 program

Phase 2Lundbeck logo

Lundbeck

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

96%

Small molecule

22 of 23 classified programs — the dominant modality here.

4%ALL OTHERSMonoclonal antibody14%

Small molecule leads; the ring shows all 23 classified programs, each share of the total. Modality classified for 100% of 23 pipeline programs.

Analysis

Trial Status

17

clinical trials

Completed11 · 65%
Not yet recruiting2 · 12%
Unknown status2 · 12%
Withdrawn1 · 6%
Terminated1 · 6%

Clinical Trials

Trial Activity

17 trials

Evaluation of an ATP-Containing Parenteral Vitamin B Complex in Patients With Symptomatic Diabetic Polyneuropathy
Not yet recruiting·EEgyptian International Pharmaceutical Industries Co·Phase 4·NCT07296354·200 enrolled
The Effect of Oral DLBS1033 in Patients With Diabetic Polyneuropathy
Not yet recruiting·UUniversitas Sebelas Maret·Phase 2/3·NCT07475065·34 enrolled
The Effect of Rosuvastatin in Diabetic Polyneuropathy: A Phase IIa Randomized Double-blind Placebo-controlled Study
Completed·AAlejandra Guillermina Miranda Diaz·Phase 2·NCT01622777·34 enrolled
Safety and Efficacy of GRT6005 in Pain Due to Diabetic Polyneuropathy
Completed·TTris Pharma, Inc.·Phase 2·NCT01347671·189 enrolled
A Study to Investigate the Analgesic Efficacy of AZD2423 Compared With Placebo After 28 Days Treatment in Patients With Painful Diabetic Polyneuropathy
Completed·AstraZeneca logoAstraZeneca·Phase 2·NCT01201317·134 enrolled
Painful Diabetic Polyneuropathy Trial With a New Centrally Acting Analgesic
Completed·TTris Pharma, Inc.·Phase 2·NCT00878293·90 enrolled
Phase IV Trial to Evaluate Efficacy of Alpha-Lipoic Acid in Treating Symptomatic Diabetic Polyneuropathy in Egypt
Completed·EEva Pharma·Phase 4·NCT05813496·430 enrolled
Actovegin® Versus Placebo in Patients With Diabetic Polyneuropathy (AV-007-IM)
Completed·NNycomed·Phase 3·NCT00483730·569 enrolled
Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Diabetic Polyneuropathy (Stage 1 or 2)
Completed·MMEDA Pharma GmbH & Co. KG·Phase 3·NCT00977483·460 enrolled
Safety and Efficacy of MCC-257 in the Treatment of Diabetic Polyneuropathy
Completed·Tanabe Pharma Corporation logoTanabe Pharma Corporation·Phase 2·NCT00307749·420 enrolled
Cytoflavin in the Treatment of Patients With Diabetic Polyneuropathy
Completed·PPOLYSAN Scientific & Technological Pharmaceutical Company·Phase 3·NCT04649203·216 enrolled
Statins for Oxidative Stress and Mitochondrial Function in Diabetic Polyneuropathy
Completed·UUniversity of Guadalajara·Phase 2·NCT02129231·74 enrolled
A Study to Demonstrate the Analgesic Efficacy of Oxycodone/Naloxone Prolonged Release Tablets in Addition to Pregabalin Compared to Pregabalin Alone in Opioid-naïve Subjects Treated With Pregabalin Suffering From Moderate to Severe Pain Due to Diabetic Polyneuropathy
Completed·MMundipharma Research GmbH & Co KG·Phase 2·NCT00944697·98 enrolled
ASP 8825 - Study in Patients With Painful Diabetic Polyneuropathy
Terminated·Astellas logoAstellas·Phase 2·NCT00508430·199 enrolled
Pharmacodynamic Study of BIIB095 and BIIB074 in Healthy Participants and Participants With Painful Diabetic Polyneuropathy
Withdrawn·Biogen logoBiogen·Phase 1·NCT04106050
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)